Physician profile
Mitchell Gittelman
NPI 1851398689
$2,069.38
in general payments reported to CMS, 2019-2025
23 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $169 · 2021: $353 · 2022: $159 · 2023: $304 · 2024: $314 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $316.22 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $303.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $301.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $241.93 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $126.45 | 2020-2025 | |
| Novo Nordisk INC | $125.94 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Mylan Specialty L.P. | $117.87 | 2021-2023 | Yupelri |
| Medtronic, INC. | $62.01 | 2021-2023 | Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.66 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $51.87 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $48.59 | 2019-2021 | |
| Amarin Pharma, INC. | $41.34 | 2019-2020 | |
| Indivior INC. | $36.40 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.30 | 2019 | |
| Amgen INC. | $30.04 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.32 | 2021-2023 | |
| Shire North American Group INC | $29.03 | 2019 | |
| Sumitomo Pharma America, INC. | $27.88 | 2025 | Gemtesa |
| Corcept Therapeutics | $22.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.99 | 2019 | |
| Dexcom, INC. | $16.78 | 2023 | Dexcom G6 Transmitter |
| Orexo US, INC. | $16.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Gittelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.